Insight Molecular Diagnostics (IMDX) Return on Capital Employed: 2020-2025
Historic Return on Capital Employed for Insight Molecular Diagnostics (IMDX) over the last 3 years, with Sep 2025 value amounting to -1.55%.
- Insight Molecular Diagnostics' Return on Capital Employed fell 86.00% to -1.55% in Q3 2025 from the same period last year, while for Sep 2025 it was -1.55%, marking a year-over-year decrease of 86.00%. This contributed to the annual value of -1.28% for FY2024, which is 97.00% down from last year.
- According to the latest figures from Q3 2025, Insight Molecular Diagnostics' Return on Capital Employed is -1.55%, which was down 18.53% from -1.31% recorded in Q2 2025.
- In the past 5 years, Insight Molecular Diagnostics' Return on Capital Employed registered a high of -0.21% during Q4 2022, and its lowest value of -1.55% during Q3 2025.
- Over the past 3 years, Insight Molecular Diagnostics' median Return on Capital Employed value was -0.69% (recorded in 2024), while the average stood at -0.91%.
- Its Return on Capital Employed has fluctuated over the past 5 years, first increased by 28bps in 2022, then tumbled by 99bps in 2024.
- Quarterly analysis of 5 years shows Insight Molecular Diagnostics' Return on Capital Employed stood at -0.50% in 2021, then increased by 28bps to -0.21% in 2022, then fell by 14bps to -0.35% in 2023, then slumped by 99bps to -1.35% in 2024, then plummeted by 86bps to -1.55% in 2025.
- Its last three reported values are -1.55% in Q3 2025, -1.31% for Q2 2025, and -1.54% during Q1 2025.